Literature DB >> 3657363

Residual and recurrent acoustic neuromas.

C W Beatty1, M J Ebersold, S G Harner.   

Abstract

A retrospective study was conducted on all 23 patients who underwent operation for residual or recurrent acoustic neuromas during the 10-year period January 1976 through December 1985. The most common symptoms at the time of reoperation were ataxia (16 patients), facial paresthesias (13 patients), and headaches (9 patients). Primary procedures had consisted of suboccipital posterior fossa approaches in 22 patients and a middle fossa approach in one. Reoperation for recurrent or residual tumor consisted of a retrosigmoid approach in 17 patients and a translabyrinthine or translabyrinthine/retrosigmoid approach in six patients. This study confirms that residual or recurrent acoustic tumors are not common. It also suggests that long-term follow-up, for at least 7 to 8 years, is indicated.

Entities:  

Mesh:

Year:  1987        PMID: 3657363     DOI: 10.1288/00005537-198710000-00009

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Vestibular schwannoma: unusual recurrence presenting as an external auditory canal mass.

Authors:  M Carreño; J L Llorente; C Suárez
Journal:  Skull Base Surg       Date:  1999

2.  Residual and recurrent acoustic neuroma in hearing preservation procedures: neuroradiologic and surgical findings.

Authors:  A Mazzoni; V Calabrese; L Moschini
Journal:  Skull Base Surg       Date:  1996

3.  Treatment of large and giant residual and recurrent vestibular schwannomas.

Authors:  Ricardo Ramina; Maurício Coelho Neto; Kelly Cristina Bordignon; Tobias Mattei; Rogério Clemente; Paulo Henrique Pires Aguiar
Journal:  Skull Base       Date:  2007-03

4.  The long-term growth rate of residual acoustic neurinomas.

Authors:  S Kameyama; R Tanaka; Y Honda; A Hasegawa; H Yamazaki; T Kawaguchi
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.